Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Adenocarcinoma × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 50 Carcinoma, Non-Small-Cell Lung 45 Carcinoma, Renal Cell 32 Neoplasms 24 Neoplasm Metastasis 21 Colorectal Neoplasms 20 Carcinoma, Hepatocellular 19 Squamous Cell Carcinoma of Head and Neck 17 Stomach Neoplasms 15 Triple Negative Breast Neoplasms 14 Ovarian Neoplasms 14 Lung Neoplasms 11 Pancreatic Neoplasms 10 Hodgkin Disease 10 Carcinoma, Transitional Cell 10 Head and Neck Neoplasms 8 Small Cell Lung Carcinoma 7 Sarcoma 7 Recurrence 7 Urinary Bladder Neoplasms 6 Prostatic Neoplasms 6 Lymphoma, Non-Hodgkin 6 Endometrial Neoplasms 6 Carcinoma, Merkel Cell 6 Breast Neoplasms 6 Advanced Cancer 6 Uterine Cervical Neoplasms 5 Glioblastoma 5 Colonic Neoplasms 5 Uveal Melanoma 4

Interventions

tocilizumab 1 selicrelumab 1 niraparib 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Panitumumab 1 PEGPH20 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Leucovorin 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Bevacizumab 1 4-fluorobenzoyl-TN-14003 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡